After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry. Yet, their ...

AbbVie ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

More than half of patients with treatment-resistant hidradenitis suppurativa achieved a 55% improvement in their disease after initiating golimumab, a tumor necrosis factor inhibitor, according to a ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...